Manuscript

perpetuity. It is made available under a CC-BY 4.0 International license .

Metabolic Syndrome and Restrictive Ventilatory Defect

Title:

The gender gap in the relationship between Metabolic Syndrome and Restrictive Ventilatory Defect

Running title: Metabolic Syndrome and Restrictive Ventilatory Defect

Authors:

Ya-Chun Chu^{a,b}; Chi-Chiang Yang^{b,c}; Shaw-Ji Chen^{b,d,e}; Pei-Ling Cheng^a; Mei-Chuan Wu^a; Hsin-Hung Wu^{f*}; Jerry Cheng-Yen Lai^{b*}

Affiliations:

^a Department of Respiratory Therapy Center, Taitung MacKay Memorial Hospital, Taitung, Taiwan. Address: No.1, Lane 303, Changsha Street, Taitung City 95054, Taiwan.
^b Master Program in Biomedicine, National Taitung University, Taitung, Taiwan.
Address: No.684, Sec. 1, Zhonghua Rd, Taitung City 95002, Taiwan.
^c Biomedicine, Agriculture, and Food Science Research Center, National Taitung University, Taitung, Taiwan.
Address: No.684, Sec. 1, Zhonghua Rd, Taitung City 95002, Taiwan.
^d Department of Psychiatry, Taitung MacKay Memorial Hospital, Taitung, Taiwan.
Address: No.1, Lane 303, Changsha Street, Taitung City 95054, Taiwan.
^e Department of Medicine, MacKay Medical College, New Taipei, Taiwan.
Address: No. 46, Section 3, Zhongzheng Rd, Sanzhi District, New Taipei City 25245, Taiwan.
^f Department of Pulmonary Medicine, Taitung MacKay Memorial Hospital, Taitung, Taiwan.

*Corresponding Authors: *Hsin-Hung Wu, MD Email: a5809@mmh.org.tw (HH Wu) ORCID: 0009-0006-0074-0190 *Jerry Cheng-Yen Lai, PhD E-mail: chengyen@hotmail.com (JC Lai) ORCID: 0000-0001-8280-144X

Metabolic Syndrome and Restrictive Ventilatory Defect

Author Contributions

Conceptualization: Ya-Chun Chu; Chi-Chiang Yang; Hsin-Hung Wu; Jerry Cheng-Yen Lai. Data curation: Ya-Chun Chu; Shaw-Ji Chen; Jerry Cheng-Yen Lai. Formal analysis: Ya-Chun Chu; Chi-Chiang Yang; Shaw-Ji Chen; Jerry Cheng-Yen Lai. Funding acquisition: Jerry Cheng-Yen Lai; Pei-Ling Cheng; Mei-Chuan Wu. Investigation: Ya-Chun Chu; Pei-Ling Cheng. Methodology: Ya-Chun Chu; Shaw-Ji Chen; Hsin-Hung Wu; Jerry Cheng-Yen Lai. Project administration: Chi-Chiang Yang; Pei-Ling Cheng; Hsin-Hung Wu. Resources: Chi-Chiang Yang; Pei-Ling Cheng; Mei-Chuan Wu. Software: Pei-Ling Cheng; Jerry Cheng-Yen Lai. Supervision: Shaw-Ji Chen; Mei-Chuan Wu; Hsin-Hung Wu; Jerry Cheng-Yen Lai. Validation: Ya-Chun Chu; Hsin-Hung Wu; Jerry Cheng-Yen Lai. Visualization: Ya-Chun Chu; Chi-Chiang Yang; Hsin-Hung Wu. Writing - orginal draft: Ya-Chun Chu; Chi-Chiang Yang; Shaw-Ji Chen; Jerry Cheng-Yen Lai. Writing - review&editing: Ya-Chun Chu; Hsin-Hung Wu; Jerry Cheng-Yen Lai.

Review of manuscript

All authors read and approved the final manuscript.

Funding Sources

This study was supported by grants TTMMH-107-07 and TTMMH-111-08 from Taitung MacKay Memorial Hospital, Taitung, Taiwan. The funding sources were not involved in the study or article preparation.

Conflict of Interest

The authors declared no conflict of interest.

Financial Conflict

none declared.

Data availability statement

The data that support the findings of this study are available from the Taiwan Biobank but restrictions apply to the availability of these data, which were used under license for this study. Data are however available from the authors upon reasonable request with the permission of Taiwan Biobank.

Metabolic Syndrome and Restrictive Ventilatory Defect

Abstract

Background: Given the fundamental physiological differences between the sexes, this study aimed to investigate the effect of metabolic syndrome on ventilatory defects stratified by sex. Methods: We conducted a nationwide, pooled, cross-sectional study. Data of 45,788 participants (men, n=15,859; women, n=29,929) aged 30 years or more were obtained from the Taiwan Biobank. Age-sex adjusted and multivariate logistic regression models were used to estimate the risk of developing impaired pulmonary function (restrictive or obstructive ventilatory defect) in individuals with or without metabolic syndromes. Separate models were also used to estimate for the risk of metabolic syndrome scores and the risk of individual metabolic abnormalities on the risk of restrictive ventilatory defect.

Results: The overall prevalence of metabolic syndrome was estimated to be 15.9% in Taiwan, much higher in men than in women (18.6% versus 14.4%). Significant association was observed on the effect of metabolic syndromes on the risk of restrictive ventilatory defect. The risk of developing restrictive ventilator defect was 35% higher in participants with metabolic syndromes (odds ratio, 1.35; 95% confidence interval, 1.26-1.45) than those without metabolic syndromes. Elevated blood pressure and triglycerides abnormality were important predictors of restrictive ventilator defect.

Sex-stratified subgroup analyses of the individual metabolic abnormalities indicated that men with abdominal obesity and women with dysglycemia were more likely to develop restrictive ventilatory defect.

Conclusion: Our study evidences suggested that metabolic syndromes were important predictors of impaired pulmonary function and increased risk of developing restrictive ventilatory defects, and its risk increased with increasing numbers of metabolic abnormalities.

Keywords: abdominal obesity, dysglycemia, gender gap, lung function, metabolic syndrome

Metabolic Syndrome and Restrictive Ventilatory Defect

Introduction 1

2	Metabolic syndrome (MetS) is a condition that includes a cluster of risk metabolic
3	abnormalities for a variety of diseases, including abdominal obesity (increasing waist circumference
4	[WC]), high blood pressure (BP), high level of fasting plasma glucose (FPG), high level of
5	triglyceride (TG), and low level of high-density lipoprotein cholesterol (HDL-C) levels. The MetS
6	prevalence rates differed considerably from as high as 39.4%-57.1% in several Western countries
7	(Finland, Italy, Mexico) to as low as 3.2%-15.5% (Poland, China, Turkey) [1]. In contrast, MetS is
8	one of the most rapidly increasing chronic conditions in the Taiwanese population. According to the
9	Nutrition and Health Survey in Taiwan, the prevalence rate of MetS has nearly tripled from 11.9%
10	in 1993 to 34.6% in 2020 in the adult population [2]. An important sequel is the increased risk of
11	cardiovascular disease, diabetes, hypertension, and hyperlipidemia in people with MetS, which is 2
12	to 6 times higher than in normal people [3]. Inadequate pulmonary ventilation would irritate the
13	medulla oblongata to compensate by rising respiratory rates. This situation may lower exercise
14	tolerance or cause shortness of breath and orthopnea. Compensation failure would contribute to
15	chronic hypoxia or muscle atrophy, and long-term respiratory failure could lead to changes in lung
16	structure, increasing the risk of pulmonary hypertension and Cor Pulmonale [4]. Given the
17	fundamental physiological differences between the sexes, women used more movement of the chest
18	and ribs than men during deep breathing, while men mainly applied the diaphragm expansion and
19	abdominal muscles to breathe [5]. The Korean National Health and Nutrition Examination Survey
20	reported that WC, BP, FPG, and HDL-C independently related to forced vital capacity of predicted

21	% (FVC % of predicted) in men while waist circumference significantly correlated with FVC
22	predicted (%) in women [6]. In contrast, in a study of 6,945 Taiwanese participants, a negative
23	correlation was reported between WC and FVC % predicted in men younger than 45 years, while
24	no correlation between metabolic abnormality and FVC % predicted was observed in women [7].
25	Despite many published studies on the association between MetS and impaired pulmonary
26	function, no consistent evidences are available in the literature by sex. We aimed to compare the
27	risk of developing impaired pulmonary function between individuals with or without MetS for each
28	gender using a nationwide, pooled, cross-sectional study design in Taiwan. We hypothesized that
29	sex was an independent predictor of impaired pulmonary functions, and the effects of MetS on
30	impaired pulmonary functions differed by sex among community-dwelling adult population in
31	Taiwan.

Metabolic Syndrome and Restrictive Ventilatory Defect

Methods 32

1. Study design and data source 33

34	We conducted a nationwide, pooled, cross-sectional study using the data obtained from the
35	Taiwan Biobank. Taiwan Biobank is a largescale biomedical research database that intends to
36	recruit 200,000 community-dwelling healthy volunteers aged 30-79 years residing in Taiwan that
37	consists of genetic and medical information as on predominantly Han Chinese-ancestry individuals
38	[8]. All participants in the Taiwan Biobank provided written informed consent before data
39	collection. The vertical data integration of the collected samples provide data accessible to the
40	community dwelling population in Taiwan. As stipulated by the Human Biobank Management Act,
41	the data of all participants were de-identified with uniquely encrypted identification numbers in the
42	Taiwan Biobank. As a reliable data source, studies using this database have been published in top-
43	tier journals [9, 10]. This study has been reviewed and approved by the Human Research Ethics
44	Review Committee of the MacKay Memorial Hospital (21MMHIS351e).

2. Study population 45

Using data released in 2021, a total of 132,720 adult participants recruited between 2008 and 46 47 2020 were available for analyses. The exclusion criteria were: (1) participants with missing information on pulmonary function (n=50,310) and metabolic abnormalities (n=47); (2) to ensure 48 49 the precision of the blood glucose and lipids test results, blood sugar test results with less than 8 hours of fasting were excluded (n=21,854); (3) to maintain homogeneity in prognosis, we excluded 50 all participants with cancers, respiratory diseases, cardiovascular diseases, and metabolic-related 51

Metabolic Syndrome and Restrictive Ventilatory Defect

52 diseases (n=13,011), and covariates due to incomplete data (n=1,710). A total of 45,788 participants

aged 30 years or more were included in the final analysis.

54 **3. Analysis of covariates**

55	Participants' residential urbanicity was defined according to Liu et al [11]. Education levels
56	were divided into college and above (university and graduate school or above), middle school
57	education (junior high and senior high school) and elementary school (elementary school or
58	illiterate). Participants were classified into never smoking, former smoking (did not smoke in recent
59	six months), or current smoking (for more than six months). The habit of drinking was defined as
60	150cc per week for 6 months, and former drinking was defined as not drinking for more than 6
61	months. Monthly exercise habits classified the participants using the metabolic equivalent for task
62	(MET) as never or seldom physical activity, doing light physical activity (monthly physical exercise
63	<1800 MET), moderate physical activity (monthly physical exercise=1800-3600 MET), or vigorous
64	physical activity (monthly physical exercise > 3600 MET) [12]. MET is a unit that estimates the
65	amount of energy (kcal/kg/hour) used by an individual during physical activity, and the values were
66	multiplied by 150 minutes as suggested by the World Health Organization [13].

67

4. Definition of metabolic abnormalities

According to the modified National Cholesterol Education Program Adult Treatment Panel III
(NCEP ATP III), individuals having at least three of the five metabolic abnormalities were
diagnosed as having MetS [14]: 1) abdominal obesity: WC ≥90 cm in men and ≥80 cm in women;
2) hypertriglyceridemia: TGs ≥ 150 mg/dL or pharmacotherapy for hyperlipidemia ; 3) reduced

Metabolic Syndrome and Restrictive Ventilatory Defect

72	HDL-C level: HDL-C < 40 mg/dL in men and < 50 mg/dL in women; 4) elevated BP: systolic
73	blood pressure \geq 130mmHg or diastolic blood pressure \geq 85 mmHg or pharmacotherapy for
74	hypertension; 5) elevated FPG \geq 100 mg/dL or pharmacotherapy for glucose-lowering medication.
75	5. Pulmonary function testing
76	The pulmonary function was performed by Lilly-type pneumotach sensor spirometer (HI-801,
77	CHEST M.I., INC, Tokyo, Japan) with specially trained technicians according to the American
78	Thoracic Society recommendations. All spirometric parameters were repeated for three or more
79	times with similar results to meet the criteria for acceptability and reproducibility. The spirometric
80	parameters were compared with the estimated values of the prediction lung function formula
81	adjusting for race, sex, age, and height, which were used to calculate FEV1 (forced expiratory
82	volume in one second) predicted %, FVC (forced vital capacity) predicted % and FEV1 to FVC
83	ratio. Respiratory dysfunction can be classified into obstructive ventilatory defect (OVD) and
84	restrictive ventilatory defect (RVD). The pulmonary function test results were classified as normal
85	ventilatory function (FEV1/FVC \geq 70%), RVD (FEV1/FVC \geq 70% & FVC<80% of predicted), and
86	OVD (FEV1/FVC < 70%) [15-18].

87 6. Statistical analysis

Chi-squared test for categorial variables and Student's t-test for continuous variables were used to compare group differences. Age-sex adjusted and multivariate logistic regression models were used to estimate the risk of developing impaired pulmonary function (RVD or OVD) between individuals with or without MetS stratified by sex and age. Separate models were also used to

- 92 estimate for the risks of metabolic syndrome scores (MSS) and individual metabolic abnormalities
- 93 on the risk of RVD. The reported P values were based on a two-tailed test, and P <0.05 indicated a
- 94 statistically significant. All data conversions and analyses were performed using SAS for Windows
- 95 release 9.4 (SAS Institute Inc, Cary, NC).

Metabolic Syndrome and Restrictive Ventilatory Defect

Results 96

1. Baseline characteristics 97

98	Table 1 compares basic demographic characteristic (age, obese status, residential urbanicity,
99	and education level), healthy lifestyle behaviors, family medical history, metabolic abnormalities,
100	and information related to pulmonary impairment between sexes. Most participants were women
101	(65.4%) aged 30-59 years, resided in urbanized community, and attended college or graduate
102	school. In general, men had a significantly higher incidences of metabolic abnormalities than
103	women, including elevated FPG (29.3% vs 17.2%), TGs (28.8% vs 15.2%), and BP (36.8% vs
104	20.7%). On the contrary, women had higher incidences of abdominal obesity (28.3% vs 19.3%) and
105	high-density cholesterol (26.8% vs 21.6%).
106	2. Effects of MetS on pulmonary function and ventilatory defect
107	The overall prevalence rate of MetS was estimated to be 15.9% in Taiwan, much higher in men
108	than in women (18.6% versus 14.4%) (Table 1). Of these, 16.7% had RVDs and 13.6% had OVDs.
109	Although higher proportion of male participants had MetS (18.6% vs 14.4%) and unhealthy
110	lifestyle behaviors (current smoking, 22.0% vs 2.9%; current drinking, 13.1% vs 1.9%) than female
111	participants in this study, rates of impaired pulmonary function were markedly higher among
112	women for both types of ventilatory defects (RVD, 18.7% vs 13.0%; OVD, 14.3% vs 12.3%). In
113	both sex strata, MetS increased risk of developing impaired pulmonary function FVC<80% (Odds
114	Ratio [OR], 1.33-1.34), similar in magnitude to that of all participants (OR, 1.34), which suggested
115	that the outcome was independent of sex. Similarly, the risks of MetS on developing impaired

116	function FEV1<80%, predicted (OR, 1.19-1.23 vs 1.22) (Table 2) and RVD (OR, 1.31-1.36 vs 1.35)
117	(Table 3) were both independent of sex. On the contrary, MetS did not increase the risk of
118	developing OVD after covariate adjustment (Table 3). Table 4 shows subgroup analysis stratified
119	by the MSS scores for the presence of metabolic abnormalities from none (MSS=0) to 5 (MSS=5).
120	In general, both men and women were associated with increased risk of developing RVD from for
121	MSS stratification of 2 to 5. Once again, the magnitude of risk for each MSS stratum for each sex
122	was similar to that of all participant, which suggested that the risk of RVD was independent of sex.
123	Table 5 compares the effects of individual metabolic abnormalities on the risk of RVD by age and
124	sex categories. In general, both men and women with elevated BP (OR, 1.27-1.46 vs 1.33) and TGs
125	(1.19 - 1.35 vs 1.22) abnormalities were more likely to develop RVD and the risks were
126	independent of both sex and age strata. Conversely, sex-stratified subgroup analyses of the
127	individual metabolic abnormalities indicated that only women with elevated FPG (OR, 1.14-1.38 vs
128	1.12) and men with abdominal obesity (OR, 1.24-1.30 vs 1.07) were more likely to develop RVD.
129	Although the risk of RVD was associated with reduced HDL-C by sex (OR, 1.10-1.14) and for all
130	participants (OR, 1.11), the risks of RVD were not statistically difference between age strata for
131	men and only statically significance in women younger than 55 years (OR, 1.13).

Metabolic Syndrome and Restrictive Ventilatory Defect

Discussion 132

133	Our study evidence suggested that men and women aged 30 years or older with MetS were
134	more likely to suffer from impaired pulmonary function and increased risk of developing RVD, and
135	its risk increased with increasing numbers of metabolic abnormalities. Despite much higher
136	prevalence of MetS and unhealthy lifestyle (smoking and drinking) behaviors in men than women,
137	similar rates of increased risk of developing RVD (31%-36%) were found in both sexes, whereas
138	the difference in the risk of OVD was not significant after adjusting for baseline demographic and
139	lifestyle behaviors. Additionally, elevated BPs and TGs were both important predictors of RVD. In
140	contrast, only men with abdominal obesity (or increasing WC) and women with dysglycemia
141	(elevating fasting blood glucose) were more likely to develop RVD. Many studies demonstrated
142	that the risk of developing RVD was associated with MetS [7, 19-24]. We observed an increased
143	risk of RVD with increasing numbers of metabolic abnormalities, which was consistent with those
144	reported by other researchers [7], [19, 25]. However, the results are not consistent in terms of the
145	correlation between MetS and OVD [26]. Lam et al. classified patients of COPD from I to IV
146	according to GOLD criteria, and found only a significant correlation between MetS and the worst
147	COPD groups [27], which came up with similar results in a study on Japanese men [28]. In another
148	study, Lee et al. study observed that diabetes is positively associated with RVD (OR:2.025, 95%
149	CI:1.264-3.244), but no correlative with OVD (OR:0.982, 95%CI:0.634-1.519). They also found
150	that subjects with RVD had the highest hs-CRP than other respiratory dysfunction [29].
151	Abdominal obesity is recognized as a major predicting factor for impaired respiratory function,

152	which has been confirmed in many studies [25, 30]. Wang et al. found that abdominal obesity
153	lowers FVC and FEV1 values but it did not affect the FEV1/FVC value [25]. Our study shows that
154	men's WC over 90 cm would decrease ventilatory function, such as FVC<80% predicted and
155	FEV1<80% predicted. In contrast, in a study of 6,945 Taiwanese participants, a negative correlation
156	was reported between waist circumference and FVC % predicted in men younger than 45 years
157	while no correlation between metabolic abnormality and FVC % predicted was observed in women
158	[7]. On the other hand, the Korean National Health and Nutrition Examination Survey in 2007
159	observed that WC, BP, FPG, and HDL-C independently related to FVC % of predicted in men
160	while WC significantly correlated with FVC predicted (%) in women [6]. Obese men present as the
161	deposit of fat in the chest, abdomen, and visceral organs, known as central obesity. In women, fat is
162	usually stored in the buttocks, thighs, hips, and subcutaneous tissue, known as peripheral obesity
163	[31]. Accumulated fat in the mediastinum and abdomen decreases the compliance of the chest wall,
164	causing breathing pattern changes. Intra-abdominal pressure and intrapleural pressure would
	eausing breathing patient enanges. Intra-abdominar pressure and intrapieural pressure would
165	slightly increase in the obese which decreases differential pressure from the atmosphere to the chest
165 166	
	slightly increase in the obese which decreases differential pressure from the atmosphere to the chest
166	slightly increase in the obese which decreases differential pressure from the atmosphere to the chest leading to a ventilatory flow limit. In addition, the downward movement of the diaphragm and
166 167	slightly increase in the obese which decreases differential pressure from the atmosphere to the chest leading to a ventilatory flow limit. In addition, the downward movement of the diaphragm and expansion of the chest would be restricted by adipose tissue in the abdomen, decreasing expiratory
166 167 168	slightly increase in the obese which decreases differential pressure from the atmosphere to the chest leading to a ventilatory flow limit. In addition, the downward movement of the diaphragm and expansion of the chest would be restricted by adipose tissue in the abdomen, decreasing expiratory reserved volume and functional residual capacity making work of breath increasing and ventilatory

172	inflammatory substances to reduce the pulmonary function. In our study, we found that men with
173	abdominal obesity (or increasing WC) and women having dysglycemia (elevating FPG) had a
174	higher risk of respiratory function (RVD) than those without these metabolic abnormalities. This
175	indicated a sex-specific association between abnormal fasting blood glucose and the secretion of
176	inflammatory substances. Kawamoto et al. reported a significant sex-specific correlation between
177	fasting blood glucose and hsCRP, and women had a large increasing amplitude than men [33].
178	Elevating hs-CRP amplitude different explained that women with high blood glucose will have a
179	higher risk of cardiovascular disease than men in the future [34]. Likewise, Adipocyte accumulation
180	due to obesity will secrete adipocytokines, such as Interleukin-6, TNF- α , interferon- γ , and leptin,
181	and stimulate the bronchial smooth muscle contraction and induce macrophages to move into the
182	alveoli provoking chronic inflammation damage alveoli and airway, and increase respiratory
182 183	alveoli provoking chronic inflammation damage alveoli and airway, and increase respiratory symptoms [35].
183	symptoms [35].
183 184	symptoms [35]. There are some limitations to be considered while interpreting our study results. First, the
183 184 185	symptoms [35]. There are some limitations to be considered while interpreting our study results. First, the measurement of the respiratory function with spirometry, rather than using the more bulky and
183 184 185 186	symptoms [35]. There are some limitations to be considered while interpreting our study results. First, the measurement of the respiratory function with spirometry, rather than using the more bulky and expensive equipment such as body plethysmography, did not provide data on total lung capacity
183 184 185 186 187	symptoms [35]. There are some limitations to be considered while interpreting our study results. First, the measurement of the respiratory function with spirometry, rather than using the more bulky and expensive equipment such as body plethysmography, did not provide data on total lung capacity and residual volume, which could have resulted in residual confounding. Nevertheless, the use of
183 184 185 186 187 188	symptoms [35]. There are some limitations to be considered while interpreting our study results. First, the measurement of the respiratory function with spirometry, rather than using the more bulky and expensive equipment such as body plethysmography, did not provide data on total lung capacity and residual volume, which could have resulted in residual confounding. Nevertheless, the use of spirometry with properly trained technicians is sufficient for early screening of respiratory function

- inflammatory substances such as hs-CPR prevent further investigation on the association between 192
- 193 inflammatory substances and impaired respiratory function.

Metabolic Syndrome and Restrictive Ventilatory Defect

Conclusion 194

195	Despite limitation, our study evidences suggested that metabolic syndromes were important
196	predictors of impaired pulmonary function and increased risk of developing restrictive ventilatory
197	defects, and its risk increased with increasing numbers of metabolic abnormalities. If gender-
198	specific prevention strategies can be tailored for individuals at increased risk of impairment
199	pulmonary function, further studies are required to determine the metabolic effects of medications

as well as modifiable lifestyle behaviors on metabolic abnormalities 200

	Men	Women	P-value
Independent Variables			
Participants, n (%)	15,859 (34.6)	· · · · ·	<.001
Age, mean (SD), y	48.8(11.3)	49.3(10.6)	<.001
Age, n (%)			
30-39 y	4,198 (26.5)		<.001
40-49 y	4,053 (25.6)		
50-59 y	4,123 (26.0)	9,513 (31.8)	
60-69 y	3,396 (21.4)	5,828 (19.5)	
>=70 y	89 (0.6)	77 (0.3)	
Residential urbanicity, n (%)			
Urban	9,329(58.8)	18,002(60.2)	.017
Suburban	5,695(35.9)	10,450(34.9)	
Rural	835(5.3)	1,477(4.9)	
Education level, n (%)			
College or graduate School	10,840 (68.4)	16,443 (54.9)	<.001
High school	, , ,	11,842 (39.6)	
No or elementary school	361 (2.3)	1,644 (5.5)	
Smoking experience, n (%)			
Never smoke	8,797 (55.5)	28,305 (94.6)	<.001
Former smoke	3,563 (22.5)	747 (2.5)	
Current smoke	3,499 (22.1)	877 (2.9)	
Drinking habits, n (%)			
Never drink	13,005 (82.0)	29,132 (97.3)	<.001
Former drink	774 (4.9)	235 (0.8)	
Current drink	2,080 (13.1)	562 (1.9)	
Monthly exercise habits, n (%)			
Never or seldom physical activity	9,428 (59.5)	18,266 (61.0)	<.001
Light physical activity		1,740 (5.8)	
Moderate physical activity	1,696 (10.7)	3,756 (12.6)	
Vigorous physical activity	4,089 (25.8)	6,167 (20.6)	
BMI, mean (SD)	25.2(3.5)		<.001
Obese status (BMI \geq 27), n(%)	4,109 (25.9)		<.001
Body fat rate, n (%)	22.9(5.3)	31.8(6.3)	<.001
Family medical history*			
Asthma	1,067(6.7)		<.001
Emphysema or Chronic bronchitis	337(2.1)		<.001
Cardiovascular disease	5,383(33.9)	, , ,	<.001
Diabetes	5,081(32.0)	, , ,	<.001
Metabolic syndrome, n (%) Metabolic abnormalities, n (%)	2,955 (18.6)	4,304 (14.4)	<.001

Metabolic Syndrome and Restrictive Ventilatory Defect

$TGs \ge 150 \text{ mg/dL}$	4,559 (28.8)	4,647 (15.5)	<.001
HDL-C<40mg/dL in men or HDL-C<50 mg/dL	3,421 (21.6)	8,005 (26.8)	<.001
in women	0,121 (2110)	0,000 (2010)	1001
SBP \geq 130mmHg or DBP \geq 85mmHg,	5,834 (36.8)	6,180 (20.7)	<.001
$WC \ge 90$ cm in men or $WC \ge 80$ cm in women	3,061 (19.3)	8,468 (28.3)	<.001
Lung function parameters			
FEV1, mean (SD), L	2.9 (0.8)	2.0 (0.6)	<.001
FVC, mean (SD), L	3.6 (0.7)	2.4 (0.5)	<.001
FEV1, % predicted	89.1 (22.0)	83.8 (22.5)	<.001
FVC, % predicted	94.2 (15.2)	91.0 (16.8)	<.001
FEV1 /FVC ratio	95.2 (20.8)	92.5 (20.7)	<.001
Lung function parameters, n (%)			
FEV1<80% predicted	4,084 (25.8)	10,667 (35.6)	<.001
FVC<80% predicted	2,348 (14.8)	6,674 (22.3)	<.001
Lung function diagnosis, n (%)			
Normal ventilatory function	11,855 (74.8)	20,025 (66.9)	<.001
Restrictive ventilatory defect	2,058 (13.0)	5,610 (18.7)	
Obstructive ventilatory defect	1,946 (12.3)	4,294 (14.3)	

Table 1. Baseline characteristics of total participants stratified by sex (N=45,788).

SD, standard deviation; Mets, metabolic syndrome; WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TGs, triglycerides; HDL-C, High-density lipoprotein Cholesterol; FVC, Forced volume capacity; FEV1, Force expiratory volume in one second; *P*-value, χ^2 test or Student *t*-test. * Family medical history of the participant's second degree of blood relatives were included in the family medical history. Cardiovascular disease consisted of vascular heart disease, coronary heart disease, arrhythmia, cardiomyopathy, congenital heart disease, hyperlipidemia, hypertension, and stroke.

Metabolic Syndrome and RVD

	FVC<80%, predicted		FEV1<80%, predicted	
Independent Variables	Age- sex-adjusted OR, (95% CI)	Multivariable-adjusted OR, (95% CI)	Age- sex-adjusted OR, (95% CI)	Multivariable-adjusted OR, (95% CI)
All participants	1.20 (1.13-1.27) ^c ***	1.34 (1.25-1.44) ^d ***	1.05 (1.00-1.11) ^c	1.22 (1.15-1.30) ^d ***
Men	1.37 (1.23-1.52) ^b ***	1.33 (1.18-1.50) ^a ***	1.18 (1.08-1.29) ^b ***	1.23 (1.11-1.36) ^a ***
Women	1.13 (1.05-1.22) ^b **	1.34 (1.23-1.46) ^e ***	0.99 (0.92-1.06) ^b	1.19 (1.10-1.29) ^e ***

Table 2. The effects of metabolic syndrome on the risk of impaired pulmonary function by sex.

BMI, body mass index; OR, Odds ratio; CI, Confidence interval; FVC, Forced volume capacity; FEV1, Force expiratory volume in one second; $P<0.05^*$, $P<0.01^{**}$, $P<0.001^{***}$ (*P*-value)

a. Odds ratio adjusted for age, smoking experience, drinking habits, monthly exercise habits, education level, residential urbanicity, BMI, body fat rate, family medical history (asthma, emphysema or chronic bronchitis, cardiovascular diseases, diabetes).

b. Odds ratio adjusted for only age.

c. Odds ratio adjusted for only sex and age.

d. Odds ratio adjusted for all variables in footnote a and sex.

e. Odds ratio adjusted for all variables in footnote a and menopausal status.

Metabolic Syndrome and RVD

	Restrictive ventilatory defect			Obstructive ventilatory defect			
Independent Variables	Age- sex-adjusted OR, (95% CI)		Multivariable-adjus OR, (95% CI)	sted	Age- sex-adjusted OR, (95% CI)		Multivariable-adjusted OR, (95% CI)
All participants	1.27 (1.19-1.35) ^c	***	1.35 (1.26-1.45) ^d	***	0.86 (0.79-0.93) ^c	***	0.97 (0.89-1.06) ^d
Men	1.44 (1.29-1.61) ^b	***	1.31 (1.16-1.49) ^a	***	0.92 (0.81-1.04) ^b		1.05 (0.91-1.21) ^a
Women	1.20 (1.11-1.30) ^b	***	1.36 (1.24-1.48) ^e	***	0.82 (0.74-0.91) ^b	**	0.92 (0.82-1.03) ^e

Table 3. The effects of metabolic syndrome on the risk of ventilatory defect with sex.

BMI, body mass index; OR, Odds ratio; CI, confidence interval; Restrictive ventilatory defect: FEV1/FVC \geq 70% and FVC, predicted% < 80%; Obstructive ventilatory defect: FEV1/FVC <70%; *P*<0.05*, *P*<0.01**, *P*<0.001*** (*P*-value)

a. Odds ratio adjusted for age, smoking experience, drinking habits, monthly exercise habits, education level, residential urbanicity, BMI, body fat rate, family medical history (asthma, emphysema or chronic bronchitis, cardiovascular diseases, diabetes).

b. Odds ratio adjusted for only age.

c. Odds ratio adjusted for only sex and age.

d. Odds ratio adjusted for all variables in footnote a and sex.

e. Odds ratio adjusted for all variables in footnote a and menopausal status.

Metabolic Syndrome and RVD

OR. (95% CI)	Non-metabolic syndrome			Metabolic syndrome		
	MSS=0	MSS=1	MSS=2	MSS=3	MSS=4	MSS=5
Multivariable-adjusted ^b	1	1.06 (0.99 -1.13)	1.21 (1.11 -1.31) ***	1.41 (1.28 -1.56) ***	1.51 (1.33 -1.72) ***	2.40 (1.94 -2.97) ***
Men ^a	1	1.15 (1.00 -1.32) *	1.34 (1.16 -1.56) ***	1.52 (1.27 -1.81) ***	1.58 (1.26 -1.99) ***	2.75 (1.87 -4.04) ***
Women ^c	1	1.04 (0.96 -1.13)	1.16 (1.06 -1.28) **	1.38 (1.23 -1.55) ***	1.49 (1.27 -1.74) ***	2.26 (1.75 -2.91) ***

Table 4. The effects of metabolic syndrome scores on the risk of restrictive ventilatory defect by sex.

BMI, body mass index; OR, Odds ratio; CI, confidence interval; MSS, metabolic syndrome score; $P < 0.05^*$, $P < 0.01^{**}$, $P < 0.001^{***}$ (*P*-value) a. Odds ratio adjusted for age, smoking experience, drinking habits, monthly exercise habits, education level, residential urbanicity, BMI, body fat

rate, family medical history (asthma, emphysema or chronic bronchitis, cardiovascular diseases, diabetes).

b. Odds ratio adjusted for all variables in footnote a and sex.

c. Odds ratio adjusted for all variables in footnote a and menopausal status.

Metabolic Syndrome and RVD

Independent Variables

Table 5. The effects of each metabolic component on the risk of restrictive ventilatory defect by sex and age.

independent variables			
OR, (95% CI)	Whole population	Men	Women
Elevated BP ^f	1.33 (1.25-1.41) ^c ***	1.27 (1.14-1.40) ^b ***	1.36 (1.26-1.46) ^e ***
< 55 years old		1.31 (1.13-1.52) ^a ***	1.32 (1.16-1.49) ^d ***
>=55 years old		1.40 (1.22-1.61) ^a ***	1.46 (1.34-1.60) ^d ***
Elevated FPG ^g	1.12 (1.05-1.20) ^c ***	1.05 (0.94-1.16) ^b	1.15 (1.07-1.25) ^e ***
< 55 years old		1.07 (0.91-1.26) ^a	1.38 (1.21-1.57) ^d ***
>=55 years old		1.21 (1.05-1.39) ^a **	1.14 (1.04-1.26) ^d **
Reduced HDL-Ch	1.11 (1.04-1.18) ^c ***	1.14 (1.02-1.28) ^b *	1.10 (1.03-1.18) ^e **
< 55 years old		1.15 (0.98-1.36) ^a	1.13 (1.02-1.24) ^d *
>=55 years old		1.13 (0.96-1.33) ^a	1.07 (0.97-1.18) ^d
Elevated TGs ⁱ	1.22 (1.14-1.30) ^c ***	1.27 (1.15-1.42) ^b ***	1.19 (1.09-1.29) ^e ***
< 55 years old		1.35 (1.16-1.56) ^a ***	1.22 (1.07-1.38) ^d ***
>=55 years old		1.25 (1.07-1.46) ^a **	1.20 (1.08-1.34) ^d ***
Abdominal obesity ^j	1.07 (1.00-1.16) ^c *	1.26 (1.08-1.46) ^b **	1.03 (0.95-1.13) ^e
< 55 years old		1.30 (1.04-1.61) ^a *	1.09 (0.96-1.24) ^d
>=55 years old		1.24 (1.00-1.53) ^a *	1.00 (0.89-1.12) ^d

P<0.05*, P<0.01* *, P<0.001*** (P-value)

a. Odds ratio adjusted for smoking experience, drinking habits, monthly exercise habits, education level, residential urbanicity, BMI, body fat rate, family medical history (asthma, emphysema or chronic bronchitis, cardiovascular diseases, diabetes).

- b. Odds ratio adjusted for all variables in footnote a and age.
- c. Odds ratio adjusted for all variables in footnote a, sex and age.
- d. Odds ratio adjusted for all variables in footnote a and menopausal status.
- e. Odds ratio adjusted for all variables in footnote a, age and menopausal status.
- f. Elevated BP: Systolic blood pressure \geq 130 mmHg or Diastolic blood pressure \geq 85mmHg.
- g. Elevated FPG: Fasting plasma glucose $\geq 100 \text{ mg/dL}$.
- h. Reduced HDL-C: High-density lipoprotein Cholesterol<40mg/dL in men or <50 mg/dL in women.
- i. Elevated TGs: Triglycerides \geq 150 mg/dL.
- j. Abdominal obesity: Waist circumference ≥ 90 cm in men or ≥ 80 cm in women.

Metabolic Syndrome and RVD

References

- Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients [1] with type I diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 2021; 13(1):25.
- [2] Wen-Harn P. Nutrition and Health Survey in Taiwan (NAHSIT) 2017-2022. Health Promotlion Administration in Taiwan;2022:91-92
- [3] Tai TY. Metabolic syndrome prevention and control handbook. Health Promotlion Administration in Taiwan;2007:67-118
- Martinez-Pitre PJ, Sabbula BR, Cascella M. Restrictive Lung Disease. StatPearls: July 25, 2022. [4] https://www.ncbi.nlm.nih.gov/books/NBK560880/ Accessed January 25 2023.
- [5] Kaneko H and Horie J. Breathing movements of the chest and abdominal wall in healthy subjects. Respir Care 2012; 57(9):1442-1451.
- [6] Choi J H, Park S, Shin YH, Kim MY, Lee Y J. Sex differences in the relationship between metabolic syndrome and pulmonary function: the 2007 Korean National Health and Nutrition Examination Survey. Endocr J 2011; 58(6):459-465.
- [7] Lee YY, Tsao YC, Yang CK, Chuang CH, Yu W, Chen J C, Li, WC. Association between risk factors of metabolic syndrome with lung function. Eur J Clin Nutr 2020; 74(5):811-817.
- [8] Feng YA, Chen CY, Chen TT, Kuo PH, Hsu YH, Yang HI, et al. Taiwan Biobank: A rich biomedical research database of the Taiwanese population. Cell Genomics 2022; 2(11):100197.
- [9] Lu MY, Cheng HY, Lai JC, Chen SJ. The Relationship between Habitual Coffee Drinking and the Prevalence of Metabolic Syndrome in Taiwanese Adults: Evidence from the Taiwan Biobank Database. Nutrients 2022; 14(9):1867.
- [10] Hsu CL, Huang WL, Chen HH, Cheng-Yen Lai J. Non-fermented tea consumption protects against osteoporosis among Chinese male elders using the Taiwan biobank database. Sci Rep 2022; 12(1):70-79.
- CY Liu, YT Hung, YL Chuang, YJ Chen, WS Weng, JS Liu. Incorporating development [11] stratification of Taiwan townships into sampling design of large scale health interview survey. Journal of Health Management 2006; 4(1):1-22.
- Piercy K L., Troiano R P., Ballard R M., Carlson S A., Fulton J E., Galuska D A, et al. The Physical [12] Activity Guidelines for Americans. Jama 2018; 320(19):2020-2028.
- Jetté M, Sidney K, Blümchen G. Metabolic equivalents (METS) in exercise testing, [13] exercise prescription, and evaluation of functional capacity. Clin Cardiol 1990; 13(8):555-565.
- [14] Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, et al. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 2006; 186(2):367-373.
- [15] Beachey W. Respiratory Care Anatomy and Physiology: Foundations for Clinical Practice, 2th edition. Elsevier Health Sciences; 2009:43-78.
- [16] Graham B L, Steenbruggen I, Miller MR, Barjaktarevic I Z, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and

Metabolic Syndrome and RVD

European Respiratory Society Technical Statement. Am J Respir Crit Care Med 2019; 200(8):e70e88. doi: 10.1164/rccm.201908-1590ST.

- Soriano JB, Miravitlles M, García-Río F, Muñoz L, Sánchez G, Sobradillo V, et al. [17] Spirometrically-defined restrictive ventilatory defect: population variability and individual determinants. Prim Care Respir J 2012; 21(2):187-193.
- [18] Pauwels R A, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163(5):1256-1276.
- [19] Ford ES, Cunningham TJ, Mercado CI. Lung function and metabolic syndrome: Findings of National Health and Nutrition Examination Survey 2007–2010. J Diabetes 2014; 6(6):603-613.
- Leone N, Courbon D, Thomas F, Bean K, Jégo B, Levnaert B, et al. Lung function [20] impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med 2009; 179(6):509-516.
- [21] Nakajima K, Kubouchi Y, Muneyuki T, Ebata M, Eguchi S, Munakata H. A possible association between suspected restrictive pattern as assessed by ordinary pulmonary function test and the metabolic syndrome. Chest 2008; 134(4):712-718.
- Paek YJ, Jung KS, Hwang YI, Lee KS, Lee DR, Lee JU. Association between low pulmonary [22] function and metabolic risk factors in Korean adults: the Korean National Health and Nutrition Survey. Metabolism 2010; 59(9):1300-1306.
- Lin YC, Huang TJ, Yeh MH, Lin MS, Chen MY. Lung function impairment and cardiometabolic [23] risks among rural adults: implication for an aging society. BMC Public Health 2021;21(1):960-969
- [24] Fimognari FL, Pasqualetti P, Moro L, Franco A, Piccirillo G, Pastorelli R, et al. The association between metabolic syndrome and restrictive ventilatory dysfunction in older persons. J Gerontol A Biol Sci Med Sci 2007; 62(7):760-765.
- [25] Wang F, Tian D, Zhao Y, Li J, Chen X, Zhang Y. High-Density Lipoprotein Cholesterol: A Component of the Metabolic Syndrome with a New Role in Lung Function. Evid Based Complement Alternat Med 2021; 2021:6615595.
- [26] Yoon H, Gi MY, Cha J A, Yoo CU, Park SM. The association between the metabolic syndrome and metabolic syndrome score and pulmonary function in non-smoking adults. Diab Vasc Dis Res 2018; 15(2):131-138.
- Lam KB, Jordan RE, Jiang CQ, Thomas GN, Miller MR, Zhang WS, et al. Airflow obstruction and [27] metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J 2010; 35(2):317-323.
- Funakoshi Y, Omori H, Mihara S, Marubayashi T, Katoh T. Association between airflow [28] obstruction and the metabolic syndrome or its components in Japanese men. Intern Med 2010; 49(19):2093-2099.
- [29] Lee D Y and Nam SM. Association between restrictive pulmonary disease and type 2 diabetes in Koreans: A cross-sectional study. World J Diabetes 2020; 11(10):425-434.
- Lin WY, Yao CA, Wang HC, Huang KC. Impaired lung function is associated with obesity and [30] metabolic syndrome in adults. Obesity 2006; 14(9):1654-1661.

Metabolic Syndrome and RVD

- Salome CM, King GG, Berend N. Physiology of obesity and effects on lung function. J [31] Appl Physiol 2010; 108(1):206-211.
- Barcelar Jde M, Aliverti A, Rattes C, Ximenes ME, Campos SL, Brandão DC, et al. The [32] expansion of the pulmonary rib cage during breath stacking is influenced by age in obese women. PLoS One 2014; 9(11):e110959. doi: 10.1371/journal.pone.0110959.
- [33] Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, et al. Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population. Cardiovasc Diabetol 2011; 10:51-58.
- Ferrannini G, De Bacquer D, Vynckier P, De Backer G, Gyberg V, Kotseva K, et al. Gender [34] differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. Cardiovasc Diabetol 2021; 20(1):38-49.
- Iikuni N, Lam QL, Lu L, Matarese G, La Cava A. Leptin and Inflammation. Curr Immunol Rev [35] 2008; 4(2):70-79.